Search / Trial NCT06611150

Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma

Launched by SUN YAT-SEN UNIVERSITY · Sep 23, 2024

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Nasopharyngeal Carcinoma Nab Paclitaxel Concurrent Chemotherapy

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Pathologically confirmed nasopharyngeal carcinoma
  • * III-IVa (AJCC8th)
  • * age 18-70
  • * PS score 0-1
  • * normal functions to tolerate chemotherapy and radiotherapy
  • Exclusion Criteria:
  • * The presence of other malignant neoplasms within the preceding five years, with the exception of carcinoma in situ, adequately treated non-melanoma skin cancer and papillary thyroid cancer, is permitted.
  • * Symptomatic heart failure, unstable angina, myocardial infarction, active infections requiring systemic therapy, psychiatric disorders, or family and social factors

About Sun Yat Sen University

Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.

Locations

Guangzhou, Guangdong, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0